

Case PAT033617-US-PCT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1614

Bürger, Hans Michael et al.

Examiner:

INTERNATIONAL APPLICATION NO: PCT/EP2005/001077

FILED: February 03, 2005

U.S. APPLICATION NO: 10/597287

35 USC §371 DATE: June 19, 2008

FOR: Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed August 15, 2008.
- ☒ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form PTO/SB/08A/B.

- ☒ A copy of the reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A/B form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-7824

Respectfully submitted,

  
George Dohmann  
Attorney for Applicant  
Reg. No. 33,593

Date: April 25, 2011